- Company
- Keytruda sales expected to surpass 300 billion won
- by Nho, Byung Chul Feb 16, 2024 06:25am
- Keytruda holds a blockbuster position in the immune checkpoint inhibitors sector, with analysts expecting its sales to surpass 300 billion won. According to the distribution performance report, MSD’s Keytruda recorded 289.8 billion won, leading its sector. It was followed by BMS-Ono’s Opdivo, which accumulated 99.3 billion won up to 3
- Company
- Sobi, Handok’s partner has built competitive pipelines
- by Son, Hyung-Min Feb 16, 2024 06:03am
- Sobi, a biopharmaceutical company headquartered in Sweden, announced that it will launch its new drugs for treating rare diseases, including primary hemophagocytic lymphohistiocytosis (HLH), immune thrombocytopenia (ITP), and alkaptonuria (AKU), in Korea. Sobi and Handok have entered into a business agreement to launch in Korea. According to
- Company
- GI makes bid with its new anticancer drug as combo therapy
- by Son, Hyung-Min Feb 16, 2024 06:00am
- Korean pharmaceutical bio venture company GI Innovation is working to identify the commercialization potential of its immuno-oncology drug in combination with an NK cell therapy. GI Innovation, which succeeded in licensing out its allergy drug candidate last year, plans to show results in the field of anticancer drugs this year. According
- Company
- Booming atopic dermatitis market, Adtralza nears reimb
- by Eo, Yun-Ho Feb 16, 2024 05:59am
- Adtralza, a treatment for atopic dermatitis, is expected to be the listed for insurance reimbursement. According to the industry, LEO Pharma has completed the price negotiations with the National Health Insurance Service (NHIS) for Adtralza (tralokinumab), a treatment for atopic dermatitis with an underlying mechanism of neutralizing in
- Company
- ‘Concerned about Korea’s stroke treatment system’
- by Son, Hyung-Min Feb 15, 2024 05:58am
- The government announced the initiation of a pilot project to lay the foundation for a stroke care system, but its lack of content is being criticized by the academic society. Academics have suggested that securing human resources, establishing a compensation system, and revising the stroke disease group classification system should be made
- Company
- SK Chemical ‘will continue pharma business without selling'
- by Kim, Jin-Gu Feb 15, 2024 05:58am
- SK Chemicals made an official announcement on the 14th that it has decided not to pursue the sale of its pharmaceutical business. The company said, "Amid the various internal and external variables and a rapidly changing business environment, SK Chemicals has decided to maintain its current business portfolio and pursue stable operation
- Company
- Statin+ezetimibe combo mkt size nears ₩1 tril in KOR
- by Chon, Seung-Hyun Feb 15, 2024 05:58am
- The statin and ezetimibe combination continues to dominate the dyslipidemia treatment market. Prescriptions have more than tripled over the past 5 years, with the market size approaching nearly KRW 1 trillion. The rosuvastatin-ezetimibe combination drove market growth, posting more than KRW 600 billion in sales, while the atorvastatin-ezetimibe
- Company
- SK Chemical’s pharma biz recorded sales of 376.1 bil. won
- by Chon, Seung-Hyun Feb 14, 2024 05:40am
- SK Chemical's pharmaceutical business, which is to be sold, has reached its sales peak. The company's pharmaceuticals and new drugs under contract have demonstrated stable growth in the prescription market. On the 8th, SK Chemical reported that its pharmaceutical business generated sales of 376.1 won last year, representing an increase of 19.
- Company
- Market for Pulmicort and Pulmican soars 2.6 times in 2 years
- by Chon, Seung-Hyun Feb 14, 2024 05:40am
- Last year, the prescription market for asthma medications containing the ‘budesonide’ ingredient expanded to its largest size ever. There have been significant demands for the treatment due to the circumstances surrounding the pandemic and endemic. At the end of last year, the drug pricing increase led to manufacturing and the prescription mar
- Company
- Unstoppable sales growth of Entresto
- by Kim, Jin-Gu Feb 13, 2024 06:18am
- Novartis Korea’s Entresto, a heart failure treatment, repeatedly shows significant growth. Entresto has consistently achieved over 30% growth in sales each year since its release in October 2017, having passed six years. Since its release, Entresto has undergone five price reductions to suppress the steep increase in prescription sales
